2024
Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
Cohen J, Damsky W. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. New England Journal Of Medicine 2024, 391: 188-189. PMID: 38986070, DOI: 10.1056/nejmc2404977.Peer-Reviewed Original ResearchBiologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2020
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal Of The American Academy Of Dermatology 2020, 86: 1080-1091. PMID: 33307146, DOI: 10.1016/j.jaad.2020.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesCytokinesDermatologyHumansInterleukin-23PsoriasisRetrospective StudiesTumor Necrosis Factor-alphaConceptsParadoxical reactionSystematic reviewNecrosis factor α inhibitorsTumor necrosis factor αSpectrum of manifestationsNecrosis factor αAntibody-based therapiesInterleukin-12/23IL-23IL-12/23Clinical featuresCutaneous reactionsEczematous eruptionInflammatory disordersProinflammatory cytokinesΑ inhibitorsRetrospective analysisIL-4RαFactor αPotential mechanismsDermatologyTherapyInhibitorsAntibodiesReaction patterns